Pα+ Library: Psychedelic REMS

As potential approvals of psychedelic therapies draw closer, attention is increasingly turning to what their real-world delivery might look like. While many details remain unknown, one thing appears increasingly likely: Risk Evaluation and Mitigation Strategies (REMS) will play a significant role in shaping how FDA-approved psychedelic therapies are delivered.

REMS are additional safeguards that the FDA can require when it determines they are necessary to ensure a drug’s benefits outweigh its risks. For psychedelic therapies, we expect these programs to extend beyond relatively simple measures like medication guides and communication plans and include Elements to Assure Safe Use (ETASU).

Drawing on Spravato’s REMS as a useful comparator, we anticipate psychedelic REMS could include requirements around certified healthcare settings, patient counselling, provider training, patient registries, minimum monitoring periods, and discharge procedures. But the precise requirements are likely to differ between substances: monitoring duration could be particularly important for psilocybin and LSD, while MDMA or ibogaine may raise additional considerations.

These details could have consequences far beyond clinical safety. The design of psychedelic REMS could influence treatment capacity, provider participation, patient access, off-label use, competitive strategy, and ultimately the scalability of psychedelic therapies.

In this updated Pα+ Library entry, we explore what psychedelic REMS programs might look like, how they could differ across drug candidates, whether shared REMS are realistic, and the broader implications as the field moves closer to its first potential FDA approvals...